Edition:
United Kingdom

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

4.94USD
19 Oct 2018
Change (% chg)

$-0.04 (-0.80%)
Prev Close
$4.98
Open
$5.02
Day's High
$5.04
Day's Low
$4.86
Volume
38,320
Avg. Vol
170,848
52-wk High
$9.49
52-wk Low
$1.29

Chart for

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $85.53
Shares Outstanding(Mil.): 35.05
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -0.62 -- --
ROI: -181.73 0.21 14.27
ROE: -1,032.02 1.17 15.99

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF87.04 +1.16
Merck & Co., Inc. (MRK.N) $72.35 +0.14
Roche Holding Ltd. (ROG.S) CHF244.95 +6.40
Roche Holding Ltd. (RO.S) CHF245.20 +5.80
Eli Lilly And Co (LLY.N) $111.92 -1.39
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $13.65 -1.09

Earnings vs. Estimates